JP2006193447A - Skin care composition for external use and cosmetic treatment application method using the same - Google Patents
Skin care composition for external use and cosmetic treatment application method using the same Download PDFInfo
- Publication number
- JP2006193447A JP2006193447A JP2005004992A JP2005004992A JP2006193447A JP 2006193447 A JP2006193447 A JP 2006193447A JP 2005004992 A JP2005004992 A JP 2005004992A JP 2005004992 A JP2005004992 A JP 2005004992A JP 2006193447 A JP2006193447 A JP 2006193447A
- Authority
- JP
- Japan
- Prior art keywords
- ions
- composition
- hot spring
- water
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 52
- -1 aluminum ion Chemical class 0.000 claims abstract description 44
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 19
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 10
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 7
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 94
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 49
- 229910052742 iron Inorganic materials 0.000 claims description 41
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 31
- 239000011707 mineral Substances 0.000 claims description 31
- 210000003491 skin Anatomy 0.000 claims description 31
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 24
- 230000003647 oxidation Effects 0.000 claims description 19
- 210000002950 fibroblast Anatomy 0.000 claims description 18
- 239000004927 clay Substances 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 14
- 210000004927 skin cell Anatomy 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 230000006711 vascular endothelial growth factor production Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000016396 cytokine production Effects 0.000 claims description 4
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 21
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 13
- 102000004127 Cytokines Human genes 0.000 abstract description 6
- 108090000695 Cytokines Proteins 0.000 abstract description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 abstract description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229910001447 ferric ion Inorganic materials 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 239000006071 cream Substances 0.000 description 17
- 239000002609 medium Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- 230000020411 cell activation Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000000223 arsonoyl group Chemical group [H][As](*)(*)=O 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004993 emission spectroscopy Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical group [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- MBMLMWLHJBBADN-UHFFFAOYSA-N Ferrous sulfide Chemical compound [Fe]=S MBMLMWLHJBBADN-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- COOGPNLGKIHLSK-UHFFFAOYSA-N aluminium sulfide Chemical compound [Al+3].[Al+3].[S-2].[S-2].[S-2] COOGPNLGKIHLSK-UHFFFAOYSA-N 0.000 description 1
- LCQXXBOSCBRNNT-UHFFFAOYSA-K ammonium aluminium sulfate Chemical compound [NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCQXXBOSCBRNNT-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- KZTASAUPEDXWMQ-UHFFFAOYSA-N azane;iron(3+) Chemical compound N.[Fe+3] KZTASAUPEDXWMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、特定の金属イオンを配合した組成物に関し、特に湯の花及び／又は湯の花の抽出物もしくは酸化処理物を配合した組成物に関する。本発明の組成物は細胞賦活化作用、特にサイトカインVEGF産生促進作用に優れ、皮膚外用用組成物として有用である。また、本発明は、該組成物を使用した美容施術方法に関する。さらに、本発明の組成物は化粧品、医薬品又は食品としても有用である。 The present invention relates to a composition containing a specific metal ion, and more particularly to a composition containing a hot spring flower and / or a hot spring flower extract or an oxidized product. The composition of the present invention is excellent in a cell activation effect, particularly a cytokine VEGF production promoting effect, and is useful as a composition for external use on the skin. The present invention also relates to a cosmetic treatment method using the composition. Furthermore, the composition of this invention is useful also as cosmetics, a pharmaceutical, or a foodstuff.
天然に存在する微量金属イオンは体内においても重要な役割を果たしており、その欠乏は様々な欠乏症を引き起こす。一方、これらの金属イオンは、鉱泉水中に多く含まれ、温泉治療のように鉱泉水に全身を浸す及び／又は、飲料として摂取する等により各種効能をもたらすことが知られている。かかる効能に着目し、鉱泉水抽出成分を浴用添加剤、基礎化粧品、飲料等に配合する例が報告されている。 Naturally occurring trace metal ions play an important role in the body, and their deficiency causes various deficiencies. On the other hand, these metal ions are abundantly contained in the mineral spring water, and it is known that various effects are brought about by immersing the whole body in the mineral spring water and / or ingesting it as a beverage as in hot spring treatment. Focusing on this effect, examples have been reported in which mineral water extract components are blended into bath additives, basic cosmetics, beverages and the like.
特許文献1は湯の花に含まれている成分を効果的に取り出し、かつ、明礬泉、鉄明礬泉として効果的に用い得るようにした浴用添加剤の提供について開示している。この浴用添加剤を添加して浴湯した場合、身体の痛み、水虫のかゆみ等に効果があり、また、風呂釜が、湯の花そのものを用いる場合と比べて汚れないなどの効果があると記載されている。
特許文献2は、主成分として特定の鉱泉を配合した基礎化粧品、育毛剤又は浴用剤及びその製造方法について開示している。この鉱泉配合クリームを塗布することにより、塗布後の皮膚温度の上昇が見られ、また、該クリームの共鳴磁場分析器による測定により、該クリームは血行を良くし、硬くなる筋肉組織や靭帯・収縮腱等を柔軟にする効能効果を期待することが出来ると記載されている。 Patent Document 2 discloses a basic cosmetic, a hair restorer or a bath preparation containing a specific mineral spring as a main component and a method for producing the same. By applying this mineral spring combination cream, an increase in the skin temperature after application is observed, and by measuring the cream with a resonance magnetic field analyzer, the cream improves blood circulation and hardens muscle tissue, ligaments and contractions. It is described that the effect of softening tendons can be expected.
特許文献3は、酸性緑ばん泉水、ベントナイトを含み、皮膚トラブルを引き起こすことなく、単に塗るだけで皮膚に必要なものと不必要なものを選択して不必要な老化角質だけを必要な程度ピーリングし、又皮膚のターンオーバーを促進する作用のある、長期保存しても分離・変質しない化粧料を製造する方法について開示している。該化粧料を使用したピーリングにより皮膚に潤いを感じ、皮膚が滑らかになり、又は皮膚に張りが生じたと回答した人数が多く、皮膚に付着した汚れ及び老化角質を除去及び、表皮のターンオーバーを促進させ、皮膚の老化、しみの予防と治療に役立つ効果があると記載されている。 Patent Document 3 contains acidic green spring water and bentonite, and peels only unnecessary keratin by selecting only necessary and unnecessary ones by simply applying them without causing skin trouble. In addition, a method for producing a cosmetic material that has an action of promoting skin turnover and does not separate or change even after long-term storage is disclosed. Many people responded that the skin was moistened by peeling using the cosmetics, the skin became smooth, or the skin was stretched, removed dirt and aging stratum adhering to the skin, and turned over the epidermis. It is described as having an effect to promote and help prevent and treat skin aging and spots.
特定の皮膚疾患の治癒に着目した鉱泉含有成分の使用例としては、アトピー性皮膚炎治療用温泉水組成物（特許文献4）、ニキビ改善用鉱泉成分含有皮膚外用剤（特許文献5・6）が開示されている。 Examples of use of mineral-containing ingredients focused on healing specific skin diseases include hot spring water compositions for the treatment of atopic dermatitis (patent document 4), skin-external preparations containing mineral spring ingredients for improving acne (patent documents 5 and 6) Is disclosed.
特許文献4は、塩化ナトリウム及び海水シルビンにクエン酸塩を混合したミネラル組成物を重炭酸土類泉及び硫黄泉に添加してなるアトピー性皮膚炎の治療に有効な温泉水組成物について開示する。該組成物を用いた入浴療法と上記ミネラル組成物を日常の食事で摂取する食事療法を並行して行うことにより、アトピー性皮膚炎患者の皮膚の痒み及び出血が止まり、皮膚が滑らかになり、肌が美しくなり、保湿効果があり、また、さらに桧エキス液を該組成物に加えることで精神的ストレスが解消したと記載されている。 Patent Document 4 discloses a hot spring water composition effective for the treatment of atopic dermatitis in which a mineral composition obtained by mixing citrate with sodium chloride and seawater silvin is added to a bicarbonate earth spring and a sulfur spring. . By performing a bathing therapy using the composition and a diet therapy ingesting the mineral composition in a daily diet in parallel, the itching and bleeding of the skin of the patient with atopic dermatitis stops, the skin becomes smooth, It is described that the skin becomes beautiful and has a moisturizing effect, and that mental stress has been eliminated by adding a koji extract to the composition.
特許文献5は、特定のイオンを含む鉱泉水、明礬、緑礬を1種以上含有する湯の花又は該湯の花の溶媒抽出物の中から1種以上とクエン酸塩又はアスコルビン酸塩を含む皮膚外用剤について開示する。安定性試験、リパーゼ阻害試験、抗菌試験により、該外用剤が安定性に優れ、リパーゼ阻害及び抗菌作用を有すること、また、ニキビ、吹き出物に悩む女性を対象とした1ヶ月の使用試験により、使用感についても優れ、肌荒れ、ニキビ改善、美肌作用に対する効能効果を期待することが出来ると記載されている。 Patent Document 5 describes an external preparation for skin containing one or more of a hot spring flower containing at least one kind of mineral water, alum, and green cocoon containing a specific ion, or a citrate or ascorbate from a solvent extract of the hot water flower. It discloses about. Stability test, lipase inhibition test, antibacterial test, the external preparation has excellent stability, lipase inhibition and antibacterial action, and it is also used by 1 month use test for women suffering from acne and pimples It is also described that it is excellent in feeling and can be expected to have an effect on rough skin, acne improvement, and skin beautification.
特許文献6は緑礬泉、アルカリ性単純泉から1種以上選択される鉱泉水又は鉱泉成分を含有することを特徴とする化粧料について開示する。コプロポルフィリン阻害作用試験により、該化粧料はコプロポルフィリン阻害作用を有し、ニキビ改善を期待することが出来ると記載されている。 Patent Document 6 discloses a cosmetic characterized by containing a mineral spring water or mineral spring component selected from at least one selected from a green spring and an alkaline simple spring. According to the coproporphyrin inhibitory action test, the cosmetic has a coproporphyrin inhibitory action and can be expected to improve acne.
鉱泉水の成分はその産生地域によって大きく差がある。一方、老化肌や荒れ肌の修復には、サイトカインの分泌が密接な関わりをもっていることが知られている。
本発明者は、特定の鉱泉成分に美肌作用があるとの知見を得、さらに詳細な研究を行った結果、特定の金属イオンの組み合わせにサイトカインの産生及び線維芽細胞の増殖を伴う細胞賦活作用を見出し、本発明を完成するに至った。
The composition of the mineral water varies greatly depending on the production area. On the other hand, it is known that cytokine secretion is closely related to the repair of aging skin and rough skin.
The present inventor obtained the knowledge that a specific spa component has a skin beautifying effect, and as a result of further detailed research, as a result of a specific metal ion combination, the cell activation effect accompanied by the production of cytokines and the proliferation of fibroblasts As a result, the present invention has been completed.
すなわち、本発明は、
1) 硫酸イオン1.0〜160,000mg/L(好ましくは5.0〜80,000mg/L、より好ましくは25〜40,000mg/L)、
2) 3価の鉄イオン1.0〜20,000mg/L(好ましくは2.5〜10,000mg/L、より好ましくは5.0〜5,000mg/L)及び
3) アルミニウムイオン、マグネシウムイオン、ナトリウムイオン、及びカルシウムイオンからなる群から選択される1種以上
を含み、所望により
4) 亜硫酸イオン
を含んでもよい皮膚外用用組成物を含んでもよい、皮膚外用用組成物、及び皮膚細胞を賦活するための組成物を提供する。
That is, the present invention
1) sulfate ion 1.0 to 160,000 mg / L (preferably 5.0 to 80,000 mg / L, more preferably 25 to 40,000 mg / L),
2) Trivalent iron ions 1.0-20,000 mg / L (preferably 2.5-10,000 mg / L, more preferably 5.0-5,000 mg / L) and
3) Contains one or more selected from the group consisting of aluminum ions, magnesium ions, sodium ions, and calcium ions, and if desired
4) Provided are a composition for external use on skin, which may contain a composition for external use on skin which may contain sulfite ions, and a composition for activating skin cells.
上記の皮膚外用用組成物は、好ましくは化粧品の形態であり、より好ましくはピーリング用化粧品の形態である。ピーリング用化粧品以外の化粧品の形態である場合、硫酸イオンを、例えば1.0〜36,000mg/L(好ましくは5.0〜18,000mg/L、より好ましくは25〜9,000mg/L)含み、かつ3価の鉄イオン1.0〜72,000mg/L(好ましくは2.5〜36,000mg/L、より好ましくは5.0〜1,800mg/L) を含むものが特に好ましい。 The composition for external use on the skin is preferably in the form of a cosmetic product, more preferably in the form of a cosmetic product for peeling. When it is in the form of cosmetics other than peeling cosmetics, it contains sulfate ions, for example, 1.0 to 36,000 mg / L (preferably 5.0 to 18,000 mg / L, more preferably 25 to 9,000 mg / L), and trivalent iron Particularly preferred are those containing ions of 1.0 to 72,000 mg / L (preferably 2.5 to 36,000 mg / L, more preferably 5.0 to 1,800 mg / L).
ピーリング用化粧品の形態である場合、硫酸イオンを、例えば2500〜160,000mg/L(好ましくは5,000〜80,000mg/L、より好ましくは10,000〜40,000mg/L)含み、かつ3価の鉄イオンを、500〜32,000mg/L(好ましくは1,000〜16,000mg/L、より好ましくは2,000〜8,000mg/L)を含むものが特に好ましい。 When in the form of a peeling cosmetic, it contains sulfate ions, for example, 2500 to 160,000 mg / L (preferably 5,000 to 80,000 mg / L, more preferably 10,000 to 40,000 mg / L), and trivalent iron ions, Particularly preferred is one containing 500 to 32,000 mg / L (preferably 1,000 to 16,000 mg / L, more preferably 2,000 to 8,000 mg / L).
また、上記の皮膚細胞を賦活するための組成物は、好ましくはサイトカイン産生を促進することにより皮膚細胞を賦活するためのものであり、より好ましくはVEGF産生を促進することにより皮膚細胞を賦活するためのものであるか、同時に／又は、線維芽細胞の増殖を促進することにより皮膚細胞を賦活するためのものである。このような本発明の皮膚外用用組成物及び本発明の皮膚細胞を賦活するための組成物（以下、特別な場合を除き、「本発明の組成物」という。）はさらに、2価の鉄イオン50〜50,000mg/L(好ましくは100〜10,000mg/L、より好ましくは500〜5,000mg/L)を含んでもよいが、後述するように、2価の鉄イオンを適切な処理により3価の鉄イオンにして、3価の鉄イオンの割合を増加させた本発明の組成物（最も好ましくは、そのような処理により2価の鉄イオンを実質的に含まない本発明の組成物）は、本発明の特に好ましい実施態様一つである。なお、「実質的に含まない」とは、濃度が1mg/L以下であること、又は適切な測定方法で測定したときに測定限界下であることをいう。 The composition for activating skin cells is preferably for activating skin cells by promoting cytokine production, and more preferably activating skin cells by promoting VEGF production. And / or to activate skin cells by promoting fibroblast proliferation. Such a composition for external use of the skin of the present invention and a composition for activating the skin cells of the present invention (hereinafter referred to as “the composition of the present invention unless otherwise specified)” are further provided with divalent iron. 50 to 50,000 mg / L of ions (preferably 100 to 10,000 mg / L, more preferably 500 to 5,000 mg / L), but as described later, divalent iron ions are trivalent by appropriate treatment. The composition of the present invention in which the proportion of trivalent iron ions is increased (most preferably, the composition of the present invention substantially free of divalent iron ions by such treatment). This is one particularly preferred embodiment of the present invention. “Substantially free” means that the concentration is 1 mg / L or less, or that the concentration is below the measurement limit when measured by an appropriate measurement method.
本発明の組成物中のイオン濃度は、当業者に良く知られた方法で測定することができ、例えば、ICP発光分光分析法、JIS K 0102、衛生試験法、簡易水質分析（パックテスト）によって測定することができる。 The ion concentration in the composition of the present invention can be measured by a method well known to those skilled in the art, for example, by ICP emission spectroscopy, JIS K 0102, sanitary test method, simple water quality analysis (pack test). Can be measured.
本発明の組成物には、所望の効果を損なわない範囲で、通常の外用剤に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、抗炎症剤、抗しわ剤、肌荒れ改善剤、ニキビ用薬剤、アルカリ類、キレート剤、金属封鎖剤等の成分を配合することもできる。さらに、通常の浴用添加剤に用いられる成分である硫酸ナトリウム、炭酸水素ナトリウム、炭酸カルシウム、塩化カリウム、油性成分、乳化剤、コハク酸、生薬、無機顔料、香料、及び色素等の成分を配合することもできる。 In the composition of the present invention, fats, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, which are components used in ordinary external preparations, as long as the desired effects are not impaired. pH adjusters, antiseptics, fragrances, moisturizers, powders, UV absorbers, thickeners, pigments, antioxidants, whitening agents, anti-inflammatory agents, anti-wrinkle agents, rough skin improvers, acne agents, alkalis In addition, components such as a chelating agent and a metal sequestering agent can also be blended. In addition, ingredients such as sodium sulfate, sodium hydrogen carbonate, calcium carbonate, potassium chloride, oily ingredients, emulsifiers, succinic acid, herbal medicines, inorganic pigments, fragrances, and pigments, which are components used in ordinary bath additives, You can also.
本発明の組成物はまた、その使用目的に応じて、固形剤、半固形剤、液剤等の各種剤形の組成物に調製することが可能である。本発明の組成物はまた、化粧品、医薬部外品、医薬品のいずれの形態にもできる。化粧品である場合、スキンケア化粧品として洗顔石鹸、洗顔クリーム、洗顔フォーム、化粧水、パック、マッサージクリーム、乳液、モイスチャークリーム、リップクリーム等、メーキャップ化粧品としてファンデーション、白粉、口紅、ほほ紅、アイシャドウ等、ボディケア化粧品として石鹸、液体洗浄料、日焼け止めクリーム、入浴剤等、ヘアケア化粧品としてシャンプー、リンス、ヘアトリートメント、整髪料、ヘアトニック、育毛剤、スキャルプトリートメント等とすることができる。また、医薬品である場合、硬膏剤、軟膏剤、パップ剤、リニメント剤、ローション剤とすることができる。 The composition of the present invention can also be prepared into compositions of various dosage forms such as a solid agent, a semisolid agent, and a liquid agent depending on the purpose of use. The composition of the present invention can be in any form of cosmetics, quasi drugs, and pharmaceuticals. If it is a cosmetic, facial cleansing soap, facial cleansing cream, facial cleansing foam, lotion, pack, massage cream, milky lotion, moisturizing cream, lip balm, etc. as makeup cosmetics, foundation, white powder, lipstick, cheek red, eye shadow, etc. Body care cosmetics can be soaps, liquid cleaning agents, sun creams, bathing agents, etc., and hair care cosmetics can be shampoos, rinses, hair treatments, hair styling agents, hair tonics, hair restorers, scalp treatments, and the like. Moreover, when it is a pharmaceutical, it can be set as a plaster, an ointment, a poultice, a liniment, and a lotion.
また、本発明の組成物は、湯の花の、水又は鉱泉水抽出物を原料とすることができる。湯の花を原料としたものは、本発明の組成物の特に好ましい一態様である。本明細書中の湯の花とは、特別な場合を除き、明礬、緑礬を一種以上含有するものである。湯の花は、地下から温泉水や温泉ガスが噴出したときに岩石や粘土表面に析出するもの、又は水中に沈殿する固体状のものであり、場合によっては水に不溶の成分を含有する場合もある。 Moreover, the composition of this invention can use the water or hot spring water extract of a hot spring flower as a raw material. What uses hot spring flowers as a raw material is a particularly preferred embodiment of the composition of the present invention. Except for special cases, Yunohana in the present specification contains one or more types of alum and green cocoon. Yunohana is a solid that precipitates on the surface of rocks and clay when hot spring water or hot spring gas erupts from the basement, or a solid that precipitates in water, and may contain insoluble ingredients in some cases. .
本発明の組成物の原料としては、中でも硫化アルミニウム、硫化鉄、酸化アルミニウム、硫酸鉄を主成分に含有するものが好ましく、また、温泉の噴気を結晶化させて得られたものが特に好ましく、さらには、温泉の噴気を青粘土にあてて結晶化させて得られたものが特により好ましい。青粘土に高い温度の噴気が作用すると、噴気中の硫化ガスが粘土中のミネラルを溶解すると同時に粘土状に絹糸状に結晶化する。このような青粘土表面に結晶化した湯の花を用いることにより多量の原料入手が容易となる。 As a raw material of the composition of the present invention, among them, those containing aluminum sulfide, iron sulfide, aluminum oxide, iron sulfate as a main component are preferable, and those obtained by crystallizing hot spring fumarole are particularly preferable, Furthermore, those obtained by crystallizing hot spring fumarole against blue clay are more preferred. When a high temperature fumarole acts on blue clay, the sulfurized gas in the fumarole dissolves the minerals in the clay and at the same time crystallizes into a clay like silk thread. By using such hot water flowers crystallized on the blue clay surface, it becomes easy to obtain a large amount of raw materials.
本発明の組成物に用い得る湯の花の抽出物とは、上記の湯の花を溶媒で抽出したものである。抽出する溶媒としては、例えば、水、鉱泉水、低級アルコール類（メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール等）、多価アルコール類（グリセリン、プロピレングリコール、1,3-ブチレングリコール等）、ケトン類（アセトン、メチルケトン等）、エーテル類（ジエチルエーテル、テトラヒドロフラン等）が挙げられる。好ましくは水、鉱泉水、低級アルコール類、多価アルコール類等の極性溶媒が良く、特に好ましくは水、鉱泉水、エタノール、プロピレングリコール、1,3-ブチレングリコールが良い。これらの溶媒は一種でも二種以上を混合して用いても良い。 The hot water flower extract that can be used in the composition of the present invention is obtained by extracting the hot water flower with a solvent. Examples of the solvent to be extracted include water, mineral water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), polyhydric alcohols (glycerin, propylene glycol, 1 , 3-butylene glycol, etc.), ketones (acetone, methyl ketone, etc.), ethers (diethyl ether, tetrahydrofuran, etc.). Preferred are polar solvents such as water, mineral water, lower alcohols and polyhydric alcohols, and particularly preferred are water, mineral water, ethanol, propylene glycol and 1,3-butylene glycol. These solvents may be used alone or in combination of two or more.
本明細書中の鉱泉水とは、地中から湧き出す泉水であって、多量の固形物質又はガス状物質もしくは特殊の物質を含むものをいい、その温度を問わない。具体的には、日本温泉協会による鉱泉の規定に該当するものを指し、例えば、溶存固形物質総量（1000mg/kg以上）、CO2（250mg/kg以上）、Li+（1mg/kg以上）、Sr2+（10mg/kg以上）、Ba2+（5mg/kg以上）、Fe2++ Fe3+（10mg/kg以上）、Mn2+（10mg/kg以上）、H+（1mg/kg以上）、Br-（5mg/kg以上）、I-（1mg/kg以上）、F-（2mg/kg以上）、HAsO4 2-（1.3mg/kg以上）、HAsO2（1mg/kg以上）、総イオウ（HS-+ S2O3 2- + H2S）（1mg/kg以上）、HBO2（5mg/kg以上）、H2SiO3（50mg/kg以上）、NaHCO3（340mg/kg以上）、Rn（20x10-10c/kg以上）、及びRa（10-8mg/kg以上）の19種類のうちいずれか1種以上が該規定の含有量を満たすものをいう。 Mineral spring water in the present specification refers to spring water that springs out of the ground and contains a large amount of solid substance, gaseous substance, or special substance, regardless of its temperature. Specifically, this refers to those that fall under the rules of mineral springs by the Japan Hot Spring Association, such as total dissolved solids (1000 mg / kg or more), CO 2 (250 mg / kg or more), Li + (1 mg / kg or more), Sr 2+ (10 mg / kg or more), Ba 2+ (5 mg / kg or more), Fe 2+ + Fe 3+ (10 mg / kg or more), Mn 2+ (10 mg / kg or more), H + (1 mg / kg) above), Br - (5mg / kg or more), I - (1mg / kg or more), F - (2mg / kg or more), HAsO 4 2- (1.3mg / kg or more), HAsO 2 (1mg / kg or more) , total sulfur (HS - + S 2 O 3 2- + H 2 S) (1mg / kg or more), HBO 2 (5mg / kg or more), H 2 SiO 3 (50mg / kg or more), NaHCO 3 (340mg / kg or more), Rn (20x10 -10 c / kg or more), and Ra (10 -8 mg / kg or more) of 19 types, one or more of which satisfies the specified content.
本発明の組成物に用い得る鉱泉水は、上記に記載の鉱泉水であれば特に限定されない。例えば、長野県諏訪郡の毒沢温泉、大分県別府市の明礬温泉、栃木県塩谷郡の鶏頂山温泉、北海道亀田郡の恵山温泉等を用いることが出来る。 The mineral water that can be used in the composition of the present invention is not particularly limited as long as it is the mineral water described above. For example, it is possible to use Tomizawa Onsen in Suwa-gun, Nagano Prefecture, Meiryo Onsen in Beppu City, Oita Prefecture, Toriyama Onsen in Shioya-gun, Tochigi Prefecture, and Esan Onsen in Kameda-gun, Hokkaido.
本発明の組成物には、上記の湯の花及び／又はその抽出物をそのまま使用してもよく、必要に応じて、濃縮、希釈、濾過等の処理をして用いても良い。更に、鉱泉水や抽出液は、濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物をとして用いても良い。また、pHを調整して用いてもよい。 In the composition of the present invention, the hot water flower and / or the extract thereof may be used as they are, and may be used after being subjected to treatments such as concentration, dilution, and filtration, if necessary. Further, the mineral spring water and the extract may be subjected to a treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product. Moreover, you may adjust and use pH.
湯の花及び鉱泉水は、源泉から採取しても、市販されているものを使用しても良い。本発明の組成物には、湯の花及び／又はその抽出物の有効成分のみを用いても良い。これらは、市販されているものを使用してもよい。 Yunohana and mineral spring water may be collected from a source or commercially available. In the composition of the present invention, only the active ingredients of hot water flowers and / or extracts thereof may be used. These may use what is marketed.
本発明はまた、以下を含む工程により得られうる、皮膚外用用組成物を提供する：
1) 温泉の噴気を、青粘土（好ましくは、酸化アルミニウム、酸化鉄、酸化マグネシウム、及び酸化カルシウムを含むもの）上で、一定温度及び一定湿度で結晶化させて湯の花を得て、
2) 湯の花を水性溶媒に溶解し、
3) 溶解物を所望によりオゾン酸化処理し、そして
4) 溶解物又はオゾン酸化処理物を他の成分と配合して皮膚外用用組成物とする。
The present invention also provides a composition for external use on skin, which can be obtained by a process comprising:
1) The hot spring fumarole is crystallized on blue clay (preferably containing aluminum oxide, iron oxide, magnesium oxide, and calcium oxide) at a constant temperature and humidity to obtain a hot spring flower.
2) Dissolve Yunohana in an aqueous solvent,
3) The lysate is optionally ozone oxidized, and
4) Mix the dissolved or ozone-oxidized product with other ingredients to make a composition for external use on the skin.
上記の工程1)でいう「一定温度及び一定湿度で結晶化させ」とは、穏和な条件下で徐々に結晶化させることをいう。外気を遮断した温度・湿度一定の条件下、温泉ガス噴出場所付近敷き詰めた青粘土（モンモリロナイト）上では、約1mm／日の速度で湯の花が結晶化し得る。このようにして得られた湯の花は、単に温泉中に溶けきれずに沈殿した湯の花とは各種微量成分の種類・量・割合が異なり得る。また水への溶解性が高いものであり得る。そのため、このような湯の花を配合した組成物は、線維芽細胞賦活効果、VEGF産生促進効果、ピーリング剤による角質除去効果等がより顕著であり得る。 “Crystallizing at a constant temperature and a constant humidity” in the above step 1) means crystallization gradually under mild conditions. On the blue clay (montmorillonite) spread near the hot spring gas jetting site under the condition of constant temperature and humidity with the outside air shut off, the hot water flowers can crystallize at a rate of about 1 mm / day. The hot water flowers obtained in this way may differ in the types, amounts, and ratios of various trace components from the hot water flowers that simply settled without being dissolved in the hot spring. It can also be highly soluble in water. Therefore, a composition in which such hot water flowers are blended may have more prominent effects such as a fibroblast activation effect, a VEGF production promoting effect, and an exfoliating effect due to a peeling agent.
上記の工程2)に続いて、湯の花の溶媒抽出物をオゾン酸化処理してもよい。オゾン酸化処理により、3価の鉄イオンの割合を増加させることができる。3価の鉄イオンの割合を増加させることで、ピーリング剤として用いる場合にはアルカリ性クリームをすばやく凝固させることができ、容易にクリームと共に角質を除去することができる。また、鉄臭を減少させることができる。3価の鉄イオン1に対し、2価の鉄イオンが1.5以下である（好ましくは1以下であり、より好ましくは0.5以下であり、最も好ましくは2価の鉄イオンを実質的に含まない）組成物は、本発明の好ましい一態様である。
Subsequent to the above step 2), the solvent extract of hot water flowers may be subjected to ozone oxidation treatment. Ozone oxidation treatment can increase the proportion of trivalent iron ions. By increasing the ratio of trivalent iron ions, when used as a peeling agent, the alkaline cream can be quickly solidified, and the keratin can be easily removed together with the cream. Moreover, an iron odor can be reduced. With respect to
オゾン酸化処理は、例えば、0〜50℃で湯の花抽出物に直接オゾンガスを吹き込み、抽出物中の鉄イオンを酸化させ、2価の鉄イオンを3価の鉄イオンとすることによる。好ましくは10℃〜30℃で攪拌を常時行いながら、オゾンガスを吹き込むことにより抽出物中の鉄イオンを酸化させ、2価の鉄イオンを3価の鉄イオンとする。 The ozone oxidation treatment is performed, for example, by blowing ozone gas directly into the hot water flower extract at 0 to 50 ° C. to oxidize iron ions in the extract to convert divalent iron ions into trivalent iron ions. Preferably, while constantly stirring at 10 ° C. to 30 ° C., ozone gas is blown to oxidize iron ions in the extract to convert divalent iron ions into trivalent iron ions.
上記の工程1)〜3)に続いて、湯の花結晶化物の溶解物又はそのオゾン酸化処理物に、硫酸アンモニウム鉄（III）・12水、硫酸アンモニウムアルミニウム・12水、硫酸カリウムアルミニウム・12水、硫酸アルミニウム、塩化アルミニウム及び塩化鉄よりなる群から選択される1種以上を添加してもよい。また、湯の花結晶化物の溶解物又はそのオゾン酸化処理物を濃縮するか、又は希釈し（例えば精製水で）、加熱し（例えば約85℃で約10分間）、目的の物質（例えば水酸化鉄）を析出させ、そして濃縮しても良い。このような工程は、クリームの形態の組成物を製造するのに特に適している。 Subsequent to the above steps 1) to 3), the dissolved solution of Yunohana crystallized product or the ozone-oxidized product thereof is converted to ammonium iron (III) / 12 water, ammonium aluminum sulfate / 12 water, potassium aluminum sulfate / 12 water, aluminum sulfate. One or more selected from the group consisting of aluminum chloride and iron chloride may be added. Also, the dissolved lysate of Yunohana crystallization or its ozone-oxidized product is concentrated or diluted (for example with purified water), heated (for example at about 85 ° C. for about 10 minutes), and the target substance (for example, iron hydroxide) ) May be precipitated and concentrated. Such a process is particularly suitable for producing a composition in the form of a cream.
本発明はまた、
1) 硫酸イオン0.038mg/L以上(好ましくは0.38mg/L以上、より好ましくは3.8mg/L以上、最も好ましくは38mg/L以上)及び
2) 3価の鉄イオン0.0020mg/L以上(好ましくは0.020mg/L以上、より好ましくは0.20mg/L以上、最も好ましくは2.0mg/L以上)
を含み、所望により、
3) 2価の鉄イオン、アルミニウムイオン0.0055mg/L以上(好ましくは0.055mg/L以上、より好ましくは0.55mg/L以上、最も好ましくは5.5mg/L以上)、マグネシウムイオン、ナトリウムイオン及びカルシウムイオンからなる群から選択される1種以上
を含んでもよい、VEGFに関連する疾患若しくは状態及び／又は真皮細胞の賦活化に関連する疾患若しくは状態の処置のための組成物を提供する。このような組成物は、2価の鉄イオンを0.0049mg/L以上(好ましくは0.049mg/L以上、より好ましくは0.49mg/L以上、最も好ましくは4.9mg/L以上)含むことができるが、適切な処理により3価の鉄イオンにして、3価の鉄イオンの割合を増加させたり、2価の鉄イオンを実質的に含まないようにすることができる。
The present invention also provides
1) Sulfate ion 0.038 mg / L or more (preferably 0.38 mg / L or more, more preferably 3.8 mg / L or more, most preferably 38 mg / L or more) and
2) Trivalent iron ions 0.0020 mg / L or more (preferably 0.020 mg / L or more, more preferably 0.20 mg / L or more, most preferably 2.0 mg / L or more)
Including, if desired,
3) Divalent iron ion, aluminum ion 0.0055mg / L or more (preferably 0.055mg / L or more, more preferably 0.55mg / L or more, most preferably 5.5mg / L or more), magnesium ion, sodium ion and calcium Provided is a composition for the treatment of a disease or condition associated with VEGF and / or a disease or condition associated with activation of dermal cells, which may comprise one or more selected from the group consisting of ions. Such a composition can contain 0.0049 mg / L or more of divalent iron ions (preferably 0.049 mg / L or more, more preferably 0.49 mg / L or more, most preferably 4.9 mg / L or more). By appropriate treatment, trivalent iron ions can be formed to increase the ratio of trivalent iron ions, or can be made substantially free of divalent iron ions.
このような組成物における、各イオン濃度の上限値は、安全性、安定性、製造性等を考慮し、また、所望の効果を著しく損なわず、かつ所望の効果を無意味にするほどには他の効果を生じさせない範囲で適宜設定することができる。例えば、硫酸イオンは20,000mg/L以下(好ましくは10,000mg/L以下、より好ましくは5,000mg/L以下とすることができ、3価の鉄イオンは32,000mg/L以下(好ましくは16,000mg/L以下、より好ましくは8,000mg/以下)とすることができる。また、2価の鉄イオンは32,000mg/L以下(好ましくは16,000mg/L以下、より好ましくは8,000mg/以下)とすることができ、アルミニウムイオンは32,000mg/L以下(好ましくは16,000mg/L以下、より好ましくは8,000mg/以下)とすることができる。 In such a composition, the upper limit value of each ion concentration takes into consideration safety, stability, manufacturability, etc., and does not significantly impair the desired effect and makes the desired effect meaningless. It can be set appropriately within a range that does not cause other effects. For example, sulfate ion can be 20,000 mg / L or less (preferably 10,000 mg / L or less, more preferably 5,000 mg / L or less, and trivalent iron ion is 32,000 mg / L or less (preferably 16,000 mg / L). L2 or less, more preferably 8,000 mg / L or less, and divalent iron ions should be 32,000 mg / L or less (preferably 16,000 mg / L or less, more preferably 8,000 mg / L or less). The aluminum ion can be 32,000 mg / L or less (preferably 16,000 mg / L or less, more preferably 8,000 mg / L or less).
活性化され得るサイトカインとしては、上皮細胞増殖因子（Epidermal Growth Factor：EGF）、血小板由来増殖因子（Platelet-Derived Growth Factor：PDGF）、肝細胞増殖因子（Hepatocyte Growth Factor：HGF）、線維芽細胞増殖因子（Fibroblast Growth Factor：FGF）、血管内皮細胞増殖因子（Vascular Endotherial Growth Factor、以下VEGFと略記）、各種形質転換因子（Transforming Growth Factor：TGF）、角化細胞増殖因子（Keratinocyte Growth Factor：KGF）、インシュリン様成長因子（Insulin-like Growth Factor：IGF）、各種インターロイキン（Interleukine：IL）等が挙げられる。ある種のサイトカイン産生量増加により、皮膚の老化防止、老化予防、改善が期待できる。また、それに伴い、例えば、線維芽細胞から産生されるコラーゲン・ヒアルロン酸の量が増加すれば、皮膚の柔軟性、保湿性が向上し、はりやしわの改善が期待できる。 The cytokines that can be activated include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), and fibroblast growth. Factor (Fibroblast Growth Factor: FGF), Vascular Endotherial Growth Factor (hereinafter abbreviated as VEGF), various transforming factors (Transforming Growth Factor: TGF), keratinocyte growth factor (KGF) Insulin-like growth factor (IGF), various interleukins (IL), etc. are mentioned. By increasing the amount of certain cytokine production, skin aging prevention, aging prevention and improvement can be expected. In addition, for example, if the amount of collagen / hyaluronic acid produced from fibroblasts increases, the flexibility and moisture retention of the skin can be improved, and improvement of the wrinkles and wrinkles can be expected.
VEGFは、ヒト下垂体前葉由来細胞株の培養上清から発見された血管内皮細胞に特異性の高い増殖因子であり、培養血管内皮細胞の増殖、遊走、プロテアーゼ活性の亢進、コラーゲンゲル内での血管様構造の形成など血管新生の為のすべてのステップを促進し、in vivoでも血管新生や血管透過性を促進する。多方面にわたる研究から、VEGFは胚における血管形成や成体組織における血管新生の重要な調節因子として知られている。VEGF産生促進により、例えば、火傷のような創傷に対し、VEGFによる血管促進作用に基づく治癒の促進が期待できる。 VEGF is a vascular endothelial cell-specific growth factor discovered from the culture supernatant of a human anterior pituitary-derived cell line. Cultured vascular endothelial cell proliferation, migration, increased protease activity, collagen gel It promotes all steps of angiogenesis, such as the formation of blood vessel-like structures, and promotes angiogenesis and vascular permeability in vivo. From various studies, VEGF is known as an important regulator of angiogenesis in the embryo and angiogenesis in adult tissues. By promoting VEGF production, for example, wounds such as burns can be expected to promote healing based on the blood vessel promoting action of VEGF.
本発明において、VEGFに関連する疾患又は状態とは、VEGFの量又はVEGFの応答性の変化により、予防、治療、改善又は進行の抑制が期待される疾患又は状態を意味し、また、真皮細胞の賦活化に関連する疾患又は状態とは、真皮細胞の賦活化により予防、治療、改善又は進行の抑制が期待される疾患又は状態を意味する。具体的には、創傷、火傷、褥そう、潰瘍、外傷、老化、しわ、しみ、くすみ、乾燥、紫外線による損傷が挙げられる。 In the present invention, a VEGF-related disease or condition means a disease or condition for which prevention, treatment, improvement or suppression of progression is expected due to a change in the amount of VEGF or responsiveness of VEGF, and dermal cells The disease or condition related to the activation of is meant a disease or condition for which prevention, treatment, improvement or suppression of progression is expected by activation of dermal cells. Specific examples include wounds, burns, itching, ulcers, trauma, aging, wrinkles, spots, dullness, dryness, and damage caused by ultraviolet rays.
このような組成物は医薬品の形態とすることができ、その投与経路、投与回数は、当業者であれば適宜設計することができる。また、従来技術に基づき、投与経路等に応じた剤形に適宜製剤化することができる。 Such a composition can be in the form of a pharmaceutical, and the route of administration and the number of administrations can be appropriately designed by those skilled in the art. Moreover, based on a prior art, it can formulate suitably in the dosage form according to the administration route etc.
本発明はまた、これまで述べてきたような組成物を用いることを特徴とする、美容施術方法を提供する。このような美容施術方法としては、例えば、ピーリング、マッサージ等が挙げられる。これらの組成物は単独で用いても、2種以上を組み合わせて用いてもよく、1種又は2種以上の組成物を用いる施術を複数回繰り返してもよい。また、本発明の美容施術方法は、サロンで行っても、家庭で行ってもよい。 The present invention also provides a cosmetic treatment method characterized by using the composition as described above. Examples of such cosmetic treatment methods include peeling and massage. These compositions may be used alone or in combination of two or more kinds, and the treatment using one or more kinds of compositions may be repeated a plurality of times. Moreover, the beauty treatment method of the present invention may be performed at a salon or at home.
本発明はさらに、湯の花（好ましくは温泉の噴気を結晶化させて得られた湯の花、より好ましくは温泉の噴気を青粘土にあてて結晶化させて得られた湯の花）の、水又は鉱泉水抽出物（好ましくは、さらに水又は鉱泉水抽出物をオゾン酸化処理したもの）を原料とし；
湯の花（好ましくは温泉の噴気を結晶化させて得られた湯の花、より好ましくは温泉の噴気を青粘土にあてて結晶化させて得られた湯の花）の、水又は鉱泉水抽出物（好ましくは、さらに水又は鉱泉水抽出物をオゾン酸化処理したもの）を含む食品を提供する。湯の花の含有量は、例えば本明細書の実施例2で得られた湯の花10%抽出液を用いる場合は、最終製品である食品の重量100gあたり、湯の花抽出液として0.05〜100ml、好ましくは0.1〜50ml、より好ましくは1〜10ml用いるとよい。
The present invention further provides the extraction of water or mineral water from hot spring flowers (preferably hot water flowers obtained by crystallization of hot spring fumares, more preferably hot water flowers obtained by crystallization of hot spring fumes against blue clay). A raw material (preferably, water or mineral water extract further subjected to ozone oxidation treatment);
A water or mineral water extract (preferably, a hot spring flower obtained by crystallizing hot spring fumarium, preferably hot water flower obtained by crystallizing hot spring fumarole against blue clay), Further, a food containing water or mineral water extract obtained by ozone oxidation treatment) is provided. For example, when using the
本発明の食品は、
1) 食品重量100gあたり、3価の鉄1.0〜20,000mg(好ましくは5.0〜10,000mg、より好ましくは25〜5,000mg)を含み、所望により
2) アルミニウム、マグネシウム、ナトリウム、及びカルシウムからなる群から選択される1種以上
を含んでもよい。
The food of the present invention is
1) Contains 1.0 to 20,000 mg (preferably 5.0 to 10,000 mg, more preferably 25 to 5,000 mg) of trivalent iron per 100 g of food weight, if desired
2) One or more selected from the group consisting of aluminum, magnesium, sodium, and calcium may be included.
本明細書でいう食品には、栄養補助食品、健康食品、総合健康食品、サプリメント及び飲料が含まれる。本発明の食品には、通常の食品に用いられる成分である糖類、酸化防止剤、凝固剤、pH調整剤、増粘剤、エキス粉末、生薬、無機塩等の成分を配合することができる。本発明の食品は、固形状（例えば、カプセル、タブレット、粉末）、半固形状（例えば、ゲル、ペースト）、液状とすることができる。 As used herein, food includes nutritional supplements, health foods, general health foods, supplements and beverages. In the food of the present invention, components such as sugars, antioxidants, coagulants, pH adjusters, thickeners, extract powders, herbal medicines and inorganic salts, which are components used in ordinary foods, can be blended. The food of the present invention can be solid (for example, capsule, tablet, powder), semi-solid (for example, gel, paste), or liquid.
本発明の食品は、湯の花（好ましくは温泉の噴気を結晶化させて得られた湯の花、より好ましくは温泉の噴気を青粘土にあてて結晶化させて得られた湯の花）の、水又は鉱泉水抽出物（好ましくは、さらに水又は鉱泉水抽出物をオゾン酸化処理したもの）を原料とするので、細胞賦活化作用、特にVEGF等のサイトカインの産生促進作用等を期待し得るほか、必要なミネラル成分をバランス良く含み、また味・香りに優れたものであり得る。 The food of the present invention is water or mineral spring water of hot spring flowers (preferably hot water flowers obtained by crystallization of hot spring fumares, more preferably hot water flowers obtained by crystallization of hot spring fumes against blue clay). Since the extract (preferably, water or mineral water extract that has been subjected to ozone oxidation treatment) is used as a raw material, it can be expected to have a cell activation effect, particularly a production promotion effect of cytokines such as VEGF, etc. It contains ingredients in a well-balanced manner and can be excellent in taste and aroma.
本発明の食品の製造工程において、湯の花の、水又は鉱泉水抽出物の配合の方法は、湯の花の特性を著しく損なわない限り特に制限されない。例えば、湯の花の溶媒抽出物を定法により凍結乾燥し、得られた凍結乾燥物を、他の粉末原料と混合することにより配合しても良い。このような配合の方法は、本発明の食品を、固形状（例えば粉末状）の健康食品とする場合に特に適している。湯の花の配合量は、最終製品に含ませたい目的の成分の含量を、その食品を摂取する対象者、目的とする効果（例えば、健康維持、特定の成分の補給等）、その食品が摂取される回数等を考慮して決定し、適宜設計することができる。 In the production process of the food of the present invention, the method for blending the water or mineral water extract of the hot water is not particularly limited as long as the properties of the hot water are not significantly impaired. For example, the solvent extract of Yunohana may be freeze-dried by a conventional method, and the obtained freeze-dried product may be blended with another powder raw material. Such a blending method is particularly suitable when the food of the present invention is a solid (eg, powder) health food. The amount of Yunohana is the content of the desired ingredient to be included in the final product, the target of the person who consumes the food, the desired effect (for example, maintenance of health, supplementation of specific ingredients, etc.), and the food is consumed. It is determined in consideration of the number of times to be determined, and can be designed appropriately.
なお、これまで述べてきた本発明の組成物又は食品には、その具体的な用途（例えばピーリング用、保湿用、細胞賦活化のため、美白のため、サイトカイン産生促進のため、VEGF産生促進のため、栄養補助のため、健康維持のため）及び／又はその具体的な用い方（例えば、摂取量、摂取回数、摂取方法）を表示することができる。
［実施例］
The composition or food of the present invention described so far has specific uses (for example, for peeling, moisturizing, cell activation, whitening, for promoting cytokine production, for promoting VEGF production). Therefore, for nutritional support and health maintenance) and / or the specific usage (for example, intake, number of intakes, intake method) can be displayed.
[Example]
次に本発明を詳細に説明するため、実験例を挙げるが、本発明はなんらこれらの実施例に限定されるものではない。
実施例4〜7及び実施例12に示す表中の配合量は重量％示し、FDとはフリーズドライ加工を示す。
Next, in order to describe the present invention in detail, experimental examples are given, but the present invention is not limited to these examples.
The blending amounts in the tables shown in Examples 4 to 7 and Example 12 indicate wt%, and FD indicates freeze-drying processing.
（湯の花抽出物の製造）
別府市明礬温泉地区の温泉脈より噴出する温泉水の蒸気を、外気を遮断し、温度30〜60℃、湿度85〜100％の一定の条件下で、敷き詰めた石を通して蒸気を酸化アルミニウム、酸化第一鉄、酸化第二鉄を多量に含む青粘土に当て、約1mm/日の成長速度で表面に析出する結晶性物質を40日間結晶後、採取した。
得られた結晶性物質は硫酸アルミニウム、硫酸第一鉄、硫酸第二鉄を主成分とするが、その他に表1のような多くの成分と、その他結晶水及び微量の金属イオンを含んでいた。なお、測定は、アルミニウムイオンについてはJIS K 0102 (1998) - 58.4、硫酸イオンについては衛生試験法・注解4.2.5.3(3)、亜硫酸イオンについてはJIS K 0102 (1998) - 40.1、マグネシウムイオンについてはJIS K 0102 (1998) - 51.3、ナトリウムイオンについてはICP発光分光分析法、カルシウムイオンについてはJIS K 0102 (1998) - 50.3、I2価の鉄イオンについてはJIS K 0102 (1998) - 57.1、3価の鉄イオンについてはJIS K 0102 (1998) - 57.4およびJIS K 0102 (1998) - 57.1、により行った。
(Manufacture of hot spring flower extract)
The steam from the hot spring water erupted from the hot spring vein in the Bempu City Meiryo Onsen area shuts off the outside air, and under a certain condition of temperature 30 to 60 ° C and humidity 85 to 100%, the steam is oxidized with aluminum oxide and oxidized A crystalline material deposited on the surface at a growth rate of about 1 mm / day was collected after crystallizing for 40 days after being applied to blue clay containing a large amount of ferrous oxide and ferric oxide.
The obtained crystalline substance was mainly composed of aluminum sulfate, ferrous sulfate, and ferric sulfate, but also contained many other components as shown in Table 1, other crystal water, and a trace amount of metal ions. . In addition, the measurement is JIS K 0102 (1998)-58.4 for aluminum ions, sanitary test method / comment 4.2.5.3 (3) for sulfate ions, JIS K 0102 (1998)-40.1 for sulfite ions, and magnesium ions. Is JIS K 0102 (1998)-51.3, ICP emission spectroscopy for sodium ions, JIS K 0102 (1998)-50.3 for calcium ions, JIS K 0102 (1998)-57.1, 3 for I2 valent iron ions The valent iron ions were measured according to JIS K 0102 (1998) -57.4 and JIS K 0102 (1998) -57.1.
得られた湯の花150gを、温泉水（毒沢温泉）に室温で30〜60分浸漬し（10％（重量／容積））、湯の花抽出液を得た。この抽出液をAZCOZON OZONE GENERATOR CDO-8000 (AZCO INDUSTRIES LIMITED) を用いて15〜25℃で表2に示した各時間オゾン酸化処理して、酸化物を得た。 150 g of the obtained Yunohana was soaked in hot spring water (Tochizawa Onsen) at room temperature for 30 to 60 minutes (10% (weight / volume)) to obtain a Yunohana extract. This extract was subjected to ozone oxidation treatment at 15 to 25 ° C. for each time shown in Table 2 using AZCOZON OZONE GENERATOR CDO-8000 (AZCO INDUSTRIES LIMITED) to obtain an oxide.
得られた湯の花抽出液のオゾン酸化処理物中の鉄イオン濃度測定したところ、表2に示したとおりであった。なお、測定はパックテスト（（株）共立理化学研究所）により行った。 When the iron ion concentration in the ozone-oxidized product of the obtained hot water flower extract was measured, it was as shown in Table 2. In addition, the measurement was performed by a pack test (Kyoritsu Riken Laboratories).
(湯の花抽出液の部分オゾン酸化処理)
実施例1と同様にして得られた湯の花抽出液について、実施例１と同様のオゾン酸化処理を行った。オゾン酸化処理の度合を知る目安として、電気伝導率計（CM60G、東亜電波工業（株）製）を用いた電気伝導率の測定を行った。オゾン酸化処理の度合が増すにつれ、電気伝導率は減少する。オゾン酸化処理前19〜20mS/cmであった湯の花抽出液1.5kgにおける電気伝導率が17.5〜18.5mS/cmの値になったところでオゾン酸化処理を止め、部分オゾン酸化処理湯の花抽出液とした。
(Partial ozone oxidation treatment of Yunohana extract)
The hot water flower extract obtained in the same manner as in Example 1 was subjected to the same ozone oxidation treatment as in Example 1. As a guideline for knowing the degree of ozone oxidation treatment, the electrical conductivity was measured using an electrical conductivity meter (CM60G, manufactured by Toa Denpa Kogyo Co., Ltd.). As the degree of ozone oxidation increases, the electrical conductivity decreases. The ozone oxidation treatment was stopped when the electric conductivity in the hot water flower extract of 1.5 kg, which was 19-20 mS / cm before the ozone oxidation treatment, reached a value of 17.5-18.5 mS / cm, and a flower extract of the partial ozone oxidation treated water was obtained.
(湯の花抽出液のオゾン酸化処理)
実施例２におけるオゾン酸化処理を、抽出液中の2価鉄イオンのほぼ全量が3価鉄イオンになるまで充分に行い、オゾン酸化処理湯の花抽出液を得た。実施例２と同様の条件で測定した電気伝導率の値は16〜16.5mS/cmであった。液中の硫酸イオン、3価鉄イオン及び2価鉄イオンの濃度を測定したところ、表3に示したとおりであった。
(Ozone oxidation treatment of Yunohana extract)
The ozone oxidation treatment in Example 2 was sufficiently performed until almost the total amount of divalent iron ions in the extract became trivalent iron ions, to obtain a flower extract of ozone oxidation treated hot water. The value of electrical conductivity measured under the same conditions as in Example 2 was 16 to 16.5 mS / cm. The concentrations of sulfate ion, trivalent iron ion and divalent iron ion in the liquid were measured, and as shown in Table 3.
(オゾン酸化処理湯の花抽出液のフリーズドライ加工)
実施例３で得られたオゾン酸化処理湯の花抽出液を、フリーズドライ加工（FD）し、オゾン酸化処理湯の花抽出液のフリーズドライ加工（FD）品を得た。
(Freeze-drying of flower extract of ozone-oxidized hot water)
The flower extract of ozone-oxidized hot water obtained in Example 3 was freeze-dried (FD) to obtain a freeze-dried (FD) product of flower extract of ozone-oxidized hot water.
（化粧水の製造） (Manufacture of lotion)
製造方法：
A相を75℃に加熱し、攪拌溶解する。
35℃まで冷却後、10％水溶液にしたBを加え、攪拌し、化粧水を得た。
Production method:
Heat phase A to 75 ° C. and dissolve with stirring.
After cooling to 35 ° C., 10% aqueous solution B was added and stirred to obtain a lotion.
（クリーム1、2、3の製造）
(Manufacture of
製造方法：
水相Aと油相Bをそれぞれ80℃に加熱し、溶解する。
BをAに加え、乳化機で乳化する。
乳化後、10％水溶液にしたCを加える。
35℃まで冷却し、クリームを得た。
Production method:
Water phase A and oil phase B are each heated to 80 ° C. and dissolved.
Add B to A and emulsify with an emulsifier.
After emulsification, add C in 10% aqueous solution.
Cooled to 35 ° C. to obtain a cream.
（美容液1，2の製造）
(Manufacture of
製造方法：
水相Aと油相Bをそれぞれ80℃加熱し、溶解する。
BをAに加え、乳化機で可溶化する。
35℃に冷却後、Cを加え攪拌する。
1％水溶液にしたDを加え、攪拌し、美容液を得た。
Production method:
Water phase A and oil phase B are each heated at 80 ° C. to dissolve.
Add B to A and solubilize in an emulsifier.
After cooling to 35 ° C, C is added and stirred.
D made into 1% aqueous solution was added and stirred to obtain a serum.
（石鹸の製造） (Manufacture of soap)
製造方法：
全成分を均一になるまで攪拌溶解する。
濾過、冷却固化、切断、乾燥を経て石鹸を得た。
Production method:
Stir and dissolve all ingredients until homogeneous.
A soap was obtained through filtration, cooling and solidification, cutting and drying.
（健康食品の製造） (Health food production)
製造方法：
各成分をフリーズドライしたものを混合し、健康食品を得た。
Production method:
The ingredients obtained by freeze-drying each component were mixed to obtain a health food.
（線維芽細胞賦活試験）
正常ヒト新生児由来の線維芽細胞（クラボウNHDF）を1×104cell/cm2の密度で48穴プレートに播種し、培地として10％牛胎児血清含有D-MEM（GIBCO社）を使用して、CO2インキュベーター（5％CO2、37℃）内で24時間培養した。24時間後、実施例1で得られた湯の花抽出液を1、10、100、1,000（mg/L）になるよう1％牛胎児血清含有D-MEMで調整した培地に置換し、2日間培養した。表8は、各培地中におけるイオン濃度を示す。2日後、MTT（3-(4,5-ジメチルチアゾール-2-イル)-2,5-ジフェニルテトラゾリウムブロミド）を1.0mg/ml添加したD-MEM培地に交換し、4時間培養した。生成したホルマザンを酸性イソプロパノール（0.04N塩酸になるようにイソプロパノールで調製した溶液）により抽出し、波長570nm,630nmの吸光度をプレートリーダー（BIO-TEC INSTRUMENTS, INC, EL808）で測定した。両測定値の差（570nmの吸光度−630nmの吸光度）により細胞賦活効果を評価した。コントロールとして、湯の花抽出物非添加の場合の値を100％とし、得られた結果を図1に示した（n=4）。MTT法の詳細については「分子生物学研究のための新培養細胞実験法」黒木登志夫・許南浩・千田和広編（羊土社）を参照されたい。
(Fibroblast activation test)
Normal human neonate-derived fibroblasts (Kurabo NHDF) were seeded in a 48-well plate at a density of 1 × 10 4 cells / cm 2 and 10% fetal bovine serum-containing D-MEM (GIBCO) was used as the medium. The cells were cultured for 24 hours in a CO 2 incubator (5% CO 2 , 37 ° C.). After 24 hours, the hot water flower extract obtained in Example 1 was replaced with a medium adjusted with D-MEM containing 1% fetal calf serum to 1, 10, 100, 1,000 (mg / L), and cultured for 2 days. did. Table 8 shows the ion concentration in each medium. Two days later, MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) was replaced with D-MEM medium supplemented with 1.0 mg / ml, and cultured for 4 hours. The produced formazan was extracted with acidic isopropanol (a solution prepared with isopropanol so as to become 0.04N hydrochloric acid), and the absorbance at wavelengths of 570 nm and 630 nm was measured with a plate reader (BIO-TEC INSTRUMENTS, INC, EL808). The cell activation effect was evaluated by the difference between the two measured values (absorbance at 570 nm−absorbance at 630 nm). As a control, the value when no hot water flower extract was added was taken as 100%, and the obtained results are shown in FIG. 1 (n = 4). For details of the MTT method, please refer to “New cell culture method for molecular biology research” Toshio Kuroki, Hiroshi Konan, Kazuhiro Senda (Yodosha).
図1から明らかなごとく、湯の花抽出物を培地に添加した場合、全ての濃度においてコントロールよりも線維芽細胞の賦活化効果が認められ、特に、湯の花抽出物1、10、100、1,000（mg/L）の各濃度の測定結果より、該濃度においては、濃度依存的に賦活作用が増加した。
As is clear from FIG. 1, when Yunohana extract was added to the culture medium, the effect of activating fibroblasts was observed at all concentrations as compared to the control, and in particular,
（培養真皮VEGF産生実験）
ペトリディッシュ（外径37mm）にヒアルロン酸（（株）資生堂製）より作成したヒアルロン酸スポンジを敷き、該ディッシュに10％牛胎児血清含有D-MEMを3mlを加え、30分間インキュベートした。その後余分な培地を抜き取り、コラーゲン（ブタ腱由来、タイプI 3mg/ml pH3.0）を滴下し、1時間インキュベーションした。1時間後、余分な培地を抜き取り、正常ヒト新生児由来の線維芽細胞を1×105cell/cm2の密度で播種し、24時間培養した。24時間後、実施例1で得られた湯の花抽出液を1、10、100、1,000（mg/L）になるよう1％牛胎児血清含有D-MEMで調製した培地を1ml加え、7日間培養した。7日後、培地を抜き取りエライサ法（ELISA法）により線維芽細胞から放出されたVEGFを定量した。定量にはHuman VEGF Immunoassayキット（R&D System社）を使用した。コントロールとして、湯の花抽出物非添加の場合の値を100％とし、得られた結果を図2に示す（n=4）。
(Cultivated dermal VEGF production experiment)
A hyaluronic acid sponge prepared from hyaluronic acid (manufactured by Shiseido Co., Ltd.) was spread on a petri dish (outer diameter: 37 mm), and 3 ml of D-MEM containing 10% fetal calf serum was added to the dish and incubated for 30 minutes. Thereafter, excess medium was extracted, collagen (derived from porcine tendon, type I 3 mg / ml pH 3.0) was added dropwise and incubated for 1 hour. After 1 hour, the excess medium was removed and fibroblasts derived from normal human newborns were seeded at a density of 1 × 10 5 cells / cm 2 and cultured for 24 hours. After 24 hours, 1 ml of the medium prepared with D-MEM containing 1% fetal bovine serum was added to the hot water flower extract obtained in Example 1 to 1, 10, 100, 1,000 (mg / L) and cultured for 7 days. did. Seven days later, the medium was removed and VEGF released from fibroblasts was quantified by the ELISA method (ELISA method). Human VEGF Immunoassay kit (R & D System) was used for quantification. As a control, the value when no hot water flower extract was added was taken as 100%, and the results obtained are shown in FIG. 2 (n = 4).
図2から明らかなごとく、湯の花抽出物を培地に添加した場合、コントロールよりもVEGF濃度が高く、濃度依存的に増加している。従って本発明組成物はVEGF産生促進作用を有することがわかった。 As is clear from FIG. 2, when Yunohana extract was added to the medium, the VEGF concentration was higher than the control and increased in a concentration-dependent manner. Therefore, it was found that the composition of the present invention has a VEGF production promoting action.
（培養真皮線維芽細胞賦活試験）
実施例１１と同様に正常ヒト新生児由来の線維芽細胞を湯の花抽出液含有培地中で培養後、培地を抜き取り、MTTを0.5mg/ml添加したD-MEM培地を加え、4時間培養した。産生したホルマザンを酸性イソプロパノールにより抽出し、波長570nm、630nmの吸光度を測定した。両測定値の差により、培養真皮中の線維芽細胞賦活効果を評価した。コントロールとして湯の花抽出物非添加の場合の値を100％とし、得られた結果を図3に示した（n=4）。
(Cultural dermal fibroblast activation test)
In the same manner as in Example 11, fibroblasts derived from normal human newborns were cultured in a hot spring flower extract-containing medium, the medium was extracted, and D-MEM medium supplemented with 0.5 mg / ml of MTT was added and cultured for 4 hours. The produced formazan was extracted with acidic isopropanol, and the absorbance at wavelengths of 570 nm and 630 nm was measured. The fibroblast activation effect in the cultured dermis was evaluated by the difference between the two measured values. As a control, the value when no hot water flower extract was added was taken as 100%, and the obtained results are shown in FIG. 3 (n = 4).
図3から明らかなごとく、湯の花抽出物を培地に添加した場合、コントロールよりも培養真皮中の線維芽細胞の賦活作用が高く、該濃度において濃度依存的に賦活作用が増加する傾向が認められた。 As is apparent from FIG. 3, when Yunohana extract was added to the medium, the activation effect of fibroblasts in the cultured dermis was higher than that of the control, and the activation effect tended to increase in a concentration-dependent manner at the concentration. .
（ピーリング剤の製造）
下表の処方で、施術用クリーム、ピーリング化粧水1、2及びそれらの比較例を製造した。
施術用クリーム
(Manufacture of peeling agent)
A cream for treatment, peeling
Treatment cream
製造方法：
水相A及び油相Bをそれぞれ80℃に加熱し、溶解する。
BをAに加え、乳化機で乳化する。
乳化後、10％水溶液にしたCを加える。
35℃まで冷却し、施術用クリームを得た。
ピーリング化粧水
Production method:
Water phase A and oil phase B are each heated to 80 ° C. and dissolved.
Add B to A and emulsify with an emulsifier.
After emulsification, add C in 10% aqueous solution.
After cooling to 35 ° C., a cream for treatment was obtained.
Peeling lotion
製造方法：
A相を75℃に加熱し溶解させる。
35℃まで冷却し、Bを加え攪拌する。
Cを加え攪拌溶解させ、ピーリング化粧水を得た。
Production method:
Heat phase A to 75 ° C. to dissolve.
Cool to 35 ° C, add B and stir.
C was added and dissolved by stirring to obtain a peeling lotion.
（美容施術）
肌のくすみ、老化に悩む女性を対象に、美容施術を行った。皮膚表層を膨張させ、柔軟にするため、実施例１３で製造した施術用クリームを塗布し、空気を含ませるようホイップし、約1分間放置後実施例１３で製造したピーリング化粧水（濃縮液）を滴下し、凝固させながら手指によってクリームの除去を行った。
(Cosmetics)
Beauty treatment was performed for women who suffer from dull skin and aging. In order to swell and soften the skin surface layer, the treatment cream produced in Example 13 was applied, whipped to contain air, left for about 1 minute, and then peeled lotion produced in Example 13 (concentrated liquid). Was dropped and the cream was removed with fingers while solidifying.
施術の結果、肌の明度が上がり、透明感が出た。更にざらつきが改善され、滑らかになった。乾燥状態であった肌がしっとりし、柔軟性が高まった。 As a result of the treatment, the lightness of the skin was increased and the skin became transparent. Furthermore, the roughness was improved and smoothed. The dry skin was moist and softened.
Claims (9)
2) 3価の鉄イオン1.0〜32,000mg/L(好ましくは2.5〜16,000mg/L、より好ましくは5.0〜8,000mg/L)及び
3) アルミニウムイオン、マグネシウムイオン、ナトリウムイオン、及びカルシウムイオンからなる群から選択される1種以上
を含み、所望により
4) 亜硫酸イオン
を含んでもよい皮膚外用用組成物（好ましくは化粧品の形態である組成物、より好ましくはピーリング用化粧品の形態である、組成物）。 1) sulfate ion 1.0 to 160,000 mg / L (preferably 5.0 to 80,000 mg / L, more preferably 25 to 40,000 mg / L),
2) Trivalent iron ions 1.0-32,000 mg / L (preferably 2.5-16,000 mg / L, more preferably 5.0-8,000 mg / L) and
3) Contains one or more selected from the group consisting of aluminum ions, magnesium ions, sodium ions, and calcium ions, and if desired
4) A composition for external use on the skin which may contain sulfite ions (preferably a composition in the form of a cosmetic, more preferably a composition in the form of a cosmetic for peeling).
2) 3価の鉄イオン1.0〜32,000mg/L(好ましくは2.5〜16,000mg/L、より好ましくは5.0〜8,000mg/L)及び
3) アルミニウムイオン、マグネシウムイオン、ナトリウムイオン、及びカルシウムイオンからなる群から選択される1種以上
を含み、所望により
4) 亜硫酸イオン
を含んでもよい、皮膚細胞を賦活するための（好ましくはサイトカイン産生を促進することにより皮膚細胞を賦活するための、より好ましくはVEGF産生を促進することにより皮膚細胞を賦活するための、及び／又は線維芽細胞の増殖を促進することにより皮膚細胞を賦活するための）組成物。 1) sulfate ion 1.0 to 160,000 mg / L (preferably 5.0 to 80,000 mg / L, more preferably 25 to 40,000 mg / L),
2) Trivalent iron ions 1.0-32,000 mg / L (preferably 2.5-16,000 mg / L, more preferably 5.0-8,000 mg / L) and
3) Contains one or more selected from the group consisting of aluminum ions, magnesium ions, sodium ions, and calcium ions, and if desired
4) To activate skin cells that may contain sulfite ions (preferably to activate skin cells by promoting cytokine production, more preferably to activate skin cells by promoting VEGF production) And / or a composition for activating skin cells by promoting fibroblast proliferation.
1) 温泉の噴気を、青粘土（好ましくは、酸化アルミニウム、酸化鉄、酸化マグネシウム、及び酸化カルシウムを含むもの）上で、一定温度及び一定湿度で結晶化させて湯の花を得て、
2) 湯の花を水性溶媒に溶解し、
3) 溶解物を所望によりオゾン酸化処理し、そして
4) 溶解物又はオゾン酸化処理物を他の成分と配合して皮膚外用用組成物とする。 A composition for external use on skin that can be obtained by a process comprising:
1) The hot spring fumarole is crystallized on blue clay (preferably containing aluminum oxide, iron oxide, magnesium oxide, and calcium oxide) at a constant temperature and humidity to obtain a hot spring flower.
2) Dissolve Yunohana in an aqueous solvent,
3) The lysate is optionally ozone oxidized, and
4) Mix the dissolved or ozone-oxidized product with other ingredients to make a composition for external use on the skin.
2) 3価の鉄イオン0.0020mg/L以上(好ましくは0.020mg/L以上、より好ましくは0.20mg/L以上、最も好ましくは2.0mg/L以上)
を含み、所望により、
3) 2価の鉄イオン0.0049mg/L以上(好ましくは0.049mg/L以上、より好ましくは0.49mg/L以上、最も好ましくは4.9mg/L以上)、アルミニウムイオン0.0055mg/L以上(好ましくは0.055mg/L以上、より好ましくは0.55mg/L以上、最も好ましくは5.5mg/L以上)、マグネシウムイオン、ナトリウムイオン及びカルシウムイオンからなる群から選択される1種以上
を含んでもよい、VEGFに関連する疾患若しくは状態及び／又は真皮細胞の賦活化に関連する疾患若しくは状態の処置のための組成物。 1) Sulfate ion 0.038 mg / L or more (preferably 0.38 mg / L or more, more preferably 3.8 mg / L or more, most preferably 38 mg / L or more) and
2) Trivalent iron ions 0.0020 mg / L or more (preferably 0.020 mg / L or more, more preferably 0.20 mg / L or more, most preferably 2.0 mg / L or more)
Including, if desired,
3) Divalent iron ions 0.0049 mg / L or more (preferably 0.049 mg / L or more, more preferably 0.49 mg / L or more, most preferably 4.9 mg / L or more), aluminum ions 0.0055 mg / L or more (preferably 0.055 mg / L or more, more preferably 0.55 mg / L or more, most preferably 5.5 mg / L or more), and may contain one or more selected from the group consisting of magnesium ions, sodium ions, and calcium ions. A composition for the treatment of a related disease or condition and / or a disease or condition related to activation of dermal cells.
1) 食品重量100gあたり、3価の鉄1.0〜20,000mg(好ましくは5.0〜10,000mg、より好ましくは25〜5,000mg)及び
2) アルミニウム、マグネシウム、ナトリウム、及びカルシウムからなる群から選択される1種以上
を含む前記食品。 A water or mineral water extract (preferably, a hot spring flower obtained by crystallizing hot spring fumarium, preferably hot water flower obtained by crystallizing hot spring fumarole against blue clay), In addition, food containing water or mineral water extract with ozone oxidation treatment):
1) 1.0 to 20,000 mg (preferably 5.0 to 10,000 mg, more preferably 25 to 5,000 mg) of trivalent iron per 100 g of food weight and
2) The food comprising at least one selected from the group consisting of aluminum, magnesium, sodium, and calcium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005004992A JP3967357B2 (en) | 2005-01-12 | 2005-01-12 | Composition for external use on skin and cosmetic treatment method using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005004992A JP3967357B2 (en) | 2005-01-12 | 2005-01-12 | Composition for external use on skin and cosmetic treatment method using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006193447A true JP2006193447A (en) | 2006-07-27 |
| JP3967357B2 JP3967357B2 (en) | 2007-08-29 |
Family
ID=36799800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005004992A Active JP3967357B2 (en) | 2005-01-12 | 2005-01-12 | Composition for external use on skin and cosmetic treatment method using the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3967357B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017214363A (en) * | 2016-05-26 | 2017-12-07 | 株式会社食健 | External preparation for skin, and method for producing the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019111415A1 (en) | 2017-12-08 | 2019-06-13 | ワミレスコスメティックス株式会社 | Cationized vesicles and composition thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01258793A (en) * | 1987-11-02 | 1989-10-16 | Nonogawa Shoji:Kk | Powder refreshing drink |
| JPH0788200A (en) * | 1993-09-24 | 1995-04-04 | Ryoichi Hidaka | Ceramic health cataplasm and its production |
| JPH07165558A (en) * | 1993-12-13 | 1995-06-27 | Bisoo:Kk | Production of peeling cosmetic |
| JPH08198726A (en) * | 1995-01-19 | 1996-08-06 | Sanyo Cafe:Kk | Production of bathing agent or massaging agent |
| JPH08268845A (en) * | 1995-03-30 | 1996-10-15 | Fuji Chem Kk | Hair nourishing agent containing very small amount of metal ion |
| JP2002326942A (en) * | 2001-05-07 | 2002-11-15 | Nonogawa Shoji Kk | Preparation for external use for skin |
| JP2004026814A (en) * | 2002-05-02 | 2004-01-29 | Yoshitaka Oku | Activating agent, and cosmetic, food additive, food product and beverage obtained by blending the same |
| JP2004024181A (en) * | 2002-06-28 | 2004-01-29 | Kenko Igakusha:Kk | Nutritional supplementary food product |
| JP2004161641A (en) * | 2002-11-12 | 2004-06-10 | Nonogawa Shoji Kk | Cosmetic |
| JP2005298462A (en) * | 2004-04-08 | 2005-10-27 | Medei Corporation:Kk | Skin care preparation for external use |
-
2005
- 2005-01-12 JP JP2005004992A patent/JP3967357B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01258793A (en) * | 1987-11-02 | 1989-10-16 | Nonogawa Shoji:Kk | Powder refreshing drink |
| JPH0788200A (en) * | 1993-09-24 | 1995-04-04 | Ryoichi Hidaka | Ceramic health cataplasm and its production |
| JPH07165558A (en) * | 1993-12-13 | 1995-06-27 | Bisoo:Kk | Production of peeling cosmetic |
| JPH08198726A (en) * | 1995-01-19 | 1996-08-06 | Sanyo Cafe:Kk | Production of bathing agent or massaging agent |
| JPH08268845A (en) * | 1995-03-30 | 1996-10-15 | Fuji Chem Kk | Hair nourishing agent containing very small amount of metal ion |
| JP2002326942A (en) * | 2001-05-07 | 2002-11-15 | Nonogawa Shoji Kk | Preparation for external use for skin |
| JP2004026814A (en) * | 2002-05-02 | 2004-01-29 | Yoshitaka Oku | Activating agent, and cosmetic, food additive, food product and beverage obtained by blending the same |
| JP2004024181A (en) * | 2002-06-28 | 2004-01-29 | Kenko Igakusha:Kk | Nutritional supplementary food product |
| JP2004161641A (en) * | 2002-11-12 | 2004-06-10 | Nonogawa Shoji Kk | Cosmetic |
| JP2005298462A (en) * | 2004-04-08 | 2005-10-27 | Medei Corporation:Kk | Skin care preparation for external use |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017214363A (en) * | 2016-05-26 | 2017-12-07 | 株式会社食健 | External preparation for skin, and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3967357B2 (en) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178636B (en) | Marine biological function cosmetic for minimizing pores | |
| KR20200026646A (en) | Cosmetic Composition for Improving Skin Condition Comprising Plant cell complex cultures to improve skin radiance and vitality | |
| CN106473996B (en) | A kind of oil-control skin anti-acne that shines repairs facial cleanser and preparation method thereof | |
| KR101810231B1 (en) | Cosmetic composition for improving acne containing propolis spicule powder | |
| KR20110086894A (en) | Cosmetic included to alkaline powder & solution of shell | |
| CN104825382A (en) | Biotechnology skin-whitening cosmetics | |
| CN105193673B (en) | A kind of clear acne repairs liquid and preparation method thereof | |
| CN107303253A (en) | It is a kind of to be used to be damaged renovation agent of skin and preparation method thereof | |
| CN103599063A (en) | Anti-aging face cream | |
| CN107184485A (en) | A kind of jasmine hot spring face cream with repair | |
| CN109260116A (en) | It is a kind of containing plant extracts to peptide skin base solution and its production technology | |
| CN112870116A (en) | Lip balm for moistening, preserving moisture and repairing lips, preparation method of lip balm, lip balm for moistening, preserving moisture and repairing lips and preparation method of lip balm | |
| CN105769670A (en) | Skin anti-aging essence and preparation method and application thereof | |
| CN103989614B (en) | A kind of whitening face cleaning facial treatment mask and preparation method thereof | |
| CN107569432A (en) | A kind of draft nourishes hand lotion of the white moisturizing of releiving of profit and preparation method thereof | |
| KR100780180B1 (en) | Chinese composition preventing loss of hair and promoting growth of hair and method for preparing the same | |
| JP2008100943A (en) | External preparation for skin having action to promote secretion of insulin-like growth factor 1 | |
| CN106333909A (en) | Emulsion for fading facial couperose skin and repairing skin and preparation method thereof | |
| JP2009242311A (en) | Scf secretion inhibitor and skin care preparation for external use for making skin pore inconspicuous | |
| JP3967357B2 (en) | Composition for external use on skin and cosmetic treatment method using the same | |
| CN109771326B (en) | Composition for whitening and repairing mask | |
| CN106333918A (en) | After-sun repair attapulgite face cream | |
| JP2001233727A (en) | Cosmetic | |
| CN105030574A (en) | Facial care composition | |
| JP2004026743A (en) | Polylysine preparation and cosmetic composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060829 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20060829 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20061019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070406 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070501 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070530 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3967357 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120608 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120608 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130608 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |